Trial reportInternational ophthalmology2025
Pentraxin-3 and Lipocalin-2 are decreased in patients with uveal effusion syndrome.
Trial report in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeUveal effusion syndrome (UES) is characterized by exudative detachments of choroid, ciliary body and retina. Like central serous chorioretinopathy (CSCR) it is associated with scleral thickening inhibiting fluid outflow. Recently, decreased levels of Lipocalin-2 (LCN2) and Pentraxin-3 (PTX3) were found in CSCR. The aim of this study was to measure these parameters in patients with UES to evaluate a possible pachychoroid continuum with UES as the maximum form.
designA randomized prospective case-control study was performed at the Ludwig Maximilians University, Department of Ophthalmology.
methodsIn patients with UES and in an age- BMI- and sex-matched control group, subfoveal choroidal thickness (SFCT) on optical coherence tomography imaging and the serum levels of PTX3 and LCN2 were measured.
results12 patients were included in each group. SFCT was significantly thicker in the UES group compared to the normal controls (p = 0.0003). LCN2 and PTX3 values tended to be lower in patients with UES (LCN2: 65.74 ± 33.81 (33.7 - 165.4) ng/ml vs. 108.8 ± 67.1 (40.8 - 261.9, p = 0.133) ng/ml PTX3: 0.82 ± 0.52 (0.13 - 2.1) ng/ml vs. 1.23 ± 0.77 (0.3 - 1.86, p = 0.260) ng/ml.
conclusionLipocalin-2 and Pentraxin-3 values, which are known to be induced by glucocorticoids, tend to be lower in patients with UES. The results suggest an impairment in the glucocorticoid receptor pathway and underline the hypothesis of a common pathophysiological pathway of CSCR and UES.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.